Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
A research study to determine the safety, efficacy, and tolerability of Therasphere® (also
known as Y-90, or Y-90 Therasphere) combined with or without sorafenib (Nexavar®), in
patients with hepatocellular carcinoma (HCC, or liver cancer), awaiting liver
transplantation.